Table 1.
Summary of patient demographic variables and year of treatment by study group
| IVPCA (N = 32) | TAP catheter (N = 31) | ASD | |
|---|---|---|---|
| Age (years) (mean ± SD)* | 50 ± 11 | 52 ± 14 | 0.15 |
| Female gender (%)* | 32 | 23 | 0.20 |
| Body mass index (kg/m2) (median [Q1, Q3])* | 31 [24, 32] | 27 [24, 31] | 0.19 |
| Month/year of treatment (median [Q1, Q3]) | 10/2008 [10/2008, 04/2009] | 10/2009 [05/2009, 04/2010] | 2.41 |
| Living donor (%) | 48 | 87 | 0.90 |
| Duration of surgery (h) (mean ± SD) | 5:59 ± 1:47 | 7:01 ± 1:34 | 0.62 |
| Estimated blood loss (cc) (median [Q1, Q3]) | 350 [188, 500] | 310 [250, 423] | 0.03 |
| Intraoperative opioids (mg) (morphine Eq., median [Q1, Q3]) | 27 [18, 38] | 30 [24, 38] | 0.22 |
| Serum creatinine POD1 (mg/dl) (mean ± SD) | 5.7 ± 3.1 | 5.7 ± 2.8 | 0.02 |
| Serum creatinine POD2 (mg/dl) (mean ± SD) | 4.4 ± 3.0 | 4.2 ± 2.8 | 0.06 |
| Postoperative acetaminophen dose (mg) (%) | |||
| 0 mg | 81 | 80 | 0.21 |
| 650 mg | 13 | 13 | |
| 1,300 mg | 6 | 0 | |
| 1,950 mg | 0 | 3 | |
| 2,600 mg | 0 | 3 | |
| Postoperative ondansetron dose (mg) (%) | |||
| 0 mg | 77 | 83 | 0.88 |
| 4 mg | 13 | 7 | |
| 8 mg | 3 | 3 | |
| 12 mg | 6 | 7 | |
ASD Absolute standardized differences—defined as the absolute value of the difference in means, mean rankings, or proportions divided by a combined estimate of standard deviation—are also reported. Asterisks denote variables used for adjustment in the analysis